Summary of the baseline patient characteristics
| Age, median (range), y | 61 (35-70) |
| Sex | 4 female, 1 male |
| Disease type | |
| Double-hit HGBCL | 2 |
| CTCL | 1 |
| Hodgkin lymphoma | 1 |
| NK/T-cell lymphoma | 1 |
| Previous lines of therapy, median (range) | 6 (3-8) |
| No. of patients with primary refractory disease | 3 |
| No. of patients refractory to second-line or subsequent therapy | 5 |
| No. of patients with previous CAR-19 | 2 |
| No. of patients with previous allogeneic HSCT | 1 |
| Tumor burden | |
| Baseline LDH, median (range) | 796 U/L (200-1 416) |
| Baseline SPD, median (range) | 2 516 mm2 (142-12 354) |
| Bone marrow involvement at baseline | 1 |
| Age, median (range), y | 61 (35-70) |
| Sex | 4 female, 1 male |
| Disease type | |
| Double-hit HGBCL | 2 |
| CTCL | 1 |
| Hodgkin lymphoma | 1 |
| NK/T-cell lymphoma | 1 |
| Previous lines of therapy, median (range) | 6 (3-8) |
| No. of patients with primary refractory disease | 3 |
| No. of patients refractory to second-line or subsequent therapy | 5 |
| No. of patients with previous CAR-19 | 2 |
| No. of patients with previous allogeneic HSCT | 1 |
| Tumor burden | |
| Baseline LDH, median (range) | 796 U/L (200-1 416) |
| Baseline SPD, median (range) | 2 516 mm2 (142-12 354) |
| Bone marrow involvement at baseline | 1 |
The data for n = 5 patients are shown. Data are numbers of patients unless otherwise indicated.
CTCL, cutaneous T-cell lymphoma; HGBCL, high-grade B-cell lymphoma; LDH, lactate dehydrogenase; SPD, sum of the products of diameters.